"Activated" STAT proteins: A paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells

Journal of Immunology

Volumn 192, Issue 1, 2014, Pages 447-458

  Trilling, Mirko ^a,b   Le, Vu Thuy Khanh ^a,b   Rashidi Alavijeh, Jassin ^a,b   Katschinski, Benjamin ^a,b   Scheller, Jürgen ^b   Rose John, Stefan ^c   Androsiac, Gabriela Elena ^b   JonjićL, Stipan ^d   Poli, Valeria ^e   Pfeffer, Klaus ^b   Hengel, Hartmut ^b,f  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY OF RIJEKA   (Croatia)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE 2; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN;

ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; ENHANCER REGION; ENZYME INHIBITION; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION; VIRUS GENE;

EID: 84891108328     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203516     Document Type: Article

References (74)

1. Polić, B., H. Hengel, A. Krmpotić, J. Trgovcich, I. Pavić, P. Luccaronin, S. Jonjić, and U. H. Koszinowski. 1998. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J. Exp. Med. 188: 1047-1054.
2. Ludwig, A., and H. Hengel. 2009. Epidemiological impact and disease burden of congenital cytomegalovirus infection in Europe. Euro Surveill. 14: 26-32.
3. Isaacs, A., and J. Lindenmann. 1957. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147: 258-267.
4. Clifford, J. L., X. Yang, E. Walch, M. Wang, and S. M. Lippman. 2003. Dominant negative signal transducer and activator of transcription 2 (STAT2) protein: stable expression blocks interferon alpha action in skin squamous cell carcinoma cells. Mol. Cancer Ther. 2: 453-459.
5. Horvath, C. M., and J. E. Darnell, Jr. 1996. The antiviral state induced by alpha interferon and gamma interferon requires transcriptionally active Stat1 protein. J. Virol. 70: 647-650.
6. Kaptein, A., V. Paillard, and M. Saunders. 1996. Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction. J. Biol. Chem. 271: 5961-5964.
7. Leung, S., S. A. Qureshi, I. M. Kerr, J. E. Darnell, Jr., and G. R. Stark. 1995. Role of STAT2 in the alpha interferon signaling pathway. Mol. Cell. Biol. 15: 1312-1317.
8. Browne, E. P., B. Wing, D. Coleman, and T. Shenk. 2001. Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs. J. Virol. 75: 12319-12330.
9. Geist, L. J., and L. Y. Dai. 1996. Cytomegalovirus modulates interleukin-6 gene expression. Transplantation 62: 653-658.
10. Almeida, G. D., C. D. Porada, S. St Jeor, and J. L. Ascensao. 1994. Human cytomegalovirus alters interleukin-6 production by endothelial cells. Blood 83: 370-376.
11. Hargett, D., and T. E. Shenk. 2010. Experimental human cytomegalovirus latency in CD14+ monocytes. Proc. Natl. Acad. Sci. USA 107: 20039-20044.
12. Huang, M. M., V. G. Kew, K. Jestice, M. R. Wills, and M. B. Reeves. 2012. Efficient human cytomegalovirus reactivation is maturation dependent in the Langerhans dendritic cell lineage and can be studied using a CD14+ experimental latency model. J. Virol. 86: 8507-8515.
13. Reeves, M. B., and T. Compton. 2011. Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase-mitogen- activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells. J. Virol. 85: 12750-12758.
14. Redpath, S., A. Angulo, N. R. Gascoigne, and P. Ghazal. 1999. Murine cytomegalovirus infection down-regulates MHC class II expression on macrophages by induction of IL-10. J. Immunol. 162: 6701-6707.
15. Kotenko, S. V., S. Saccani, L. S. Izotova, O. V. Mirochnitchenko, and S. Pestka. 2000. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc. Natl. Acad. Sci. USA 97: 1695-1700.
16. Hengel, H., U. H. Koszinowski, and K. K. Conzelmann. 2005. Viruses know it all: new insights into IFN networks. Trends Immunol. 26: 396-401.
17. Trilling, M., and H. Hengel. 2013. Cytomegaloviruses and interferons. In Cytomegaloviruses: From Molecular Pathogenesis to Intervention. M. J. Reddehase, ed. Caister Academic Press, Portland, OR, p. 277-295.
18. Abenes, G., M. Lee, E. Haghjoo, T. Tong, X. Zhan, and F. Liu. 2001. Murine cytomegalovirus open reading frame M27 plays an important role in growth and virulence in mice. J. Virol. 75: 1697-1707.
19. Lee, M., G. Abenes, X. Zhan, W. Dunn, E. Haghjoo, T. Tong, A. Tam, K. Chan, and F. Liu. 2002. Genetic analyses of gene function and pathogenesis of murine cytomegalovirus by transposon-mediated mutagenesis. J. Clin. Virol. 25(Suppl. 2): S111-S122.
20. Zhan, X., M. Lee, G. Abenes, I. Von Reis, C. Kittinunvorakoon, P. Ross-Macdonald, M. Snyder, and F. Liu. 2000. Mutagenesis of murine cytomegalovirus using a Tn3-based transposon. Virology 266: 264-274.
21. Zimmermann, A., M. Trilling, M. Wagner, M. Wilborn, I. Bubic, S. Jonjic, U. Koszinowski, and H. Hengel. 2005. A cytomegaloviral protein reveals a dual role for STAT2 in IFN-gamma signaling and antiviral responses. J. Exp. Med. 201: 1543-1553.
22. Khan, S., A. Zimmermann, M. Basler, M. Groettrup, and H. Hengel. 2004. A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction. J. Virol. 78: 1831-1842.
23. Trilling, M., V. T. Le, M. Fiedler, A. Zimmermann, E. Bleifuss, and H. Hengel. 2011. Identification of DNA-damage DNA-binding protein 1 as a conditional essential factor for cytomegalovirus replication in interferon-g-stimulated cells. PLoS Pathog. 7: e1002069.
24. Le, V. T., M. Trilling, M. Wilborn, H. Hengel, and A. Zimmermann. 2008. Human cytomegalovirus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylation. J. Gen. Virol. 89: 2416-2426.
25. Brune, W., C. Ménard, J. Heesemann, and U. H. Koszinowski. 2001. A ribonucleotide reductase homolog of cytomegalovirus and endothelial cell tropism. Science 291: 303-305.
26. Trilling, M., V. T. Le, A. Zimmermann, H. Ludwig, K. Pfeffer, G. Sutter, G. L. Smith, and H. Hengel. 2009. Gamma interferon-induced interferon regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts. J. Virol. 83: 3684-3695.
27. Maritano, D., M. L. Sugrue, S. Tininini, S. Dewilde, B. Strobl, X. Fu, V. Murray-Tait, R. Chiarle, and V. Poli. 2004. The STAT3 isoforms alpha and beta have unique and specific functions. Nat. Immunol. 5: 401-409.
28. Neubauer, H., A. Cumano, M. Müller, H. Wu, U. Huffstadt, and K. Pfeffer. 1998. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93: 397-409.
29. Brune, W., H. Hengel, and U. H. Koszinowski. 2001. A mouse model for cytomegalovirus infection. Curr. Protoc. Immunol. Chapter 19: Unit 19.7.
30. Fischer, M., J. Goldschmitt, C. Peschel, J. P. Brakenhoff, K. J. Kallen, A. Wollmer, J. Grötzinger, and S. Rose-John. 1997. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat. Biotechnol. 15: 142-145.
31. Le, V. T., M. Trilling, A. Zimmermann, and H. Hengel. 2008. Mouse cytomegalovirus inhibits beta interferon (IFN-beta) gene expression and controls activation pathways of the IFN-beta enhanceosome. J. Gen. Virol. 89: 1131-1141.
32. Meyer, T., A. Begitt, I. Lödige, M. van Rossum, and U. Vinkemeier. 2002. Constitutive and IFN-gamma-induced nuclear import of STAT1 proceed through independent pathways. EMBO J. 21: 344-354.
33. Ramsauer, K., M. Farlik, G. Zupkovitz, C. Seiser, A. Kröger, H. Hauser, and T. Decker. 2007. Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-gamma-inducible gbp2 gene. Proc. Natl. Acad. Sci. USA 104: 2849-2854.
34. Reinhard, H., V. T. Le, M. Ohlin, H. Hengel, and M. Trilling. 2011. Exploitation of herpesviral transactivation allows quantitative reporter gene-based assessment of virus entry and neutralization. PLoS ONE 6: e14532.
35. Popkin, D. L., M. A. Watson, E. Karaskov, G. P. Dunn, R. Bremner, and H. W. Virgin, IV. 2003. Murine cytomegalovirus paralyzes macrophages by blocking IFN gamma-induced promoter assembly. Proc. Natl. Acad. Sci. USA 100: 14309-14314.
36. Beadling, C., D. Guschin, B. A. Witthuhn, A. Ziemiecki, J. N. Ihle, I. M. Kerr, and D. A. Cantrell. 1994. Activation of JAK kinases and STAT proteins by interleukin-2 and interferon alpha, but not the T cell antigen receptor, in human T lymphocytes. EMBO J. 13: 5605-5615.
37. Hengel, H., P. Lucin, S. Jonjić, T. Ruppert, and U. H. Koszinowski. 1994. Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J. Virol. 68: 289-297.
38. Angulo, A., P. Ghazal, and M. Messerle. 2000. The major immediate-early gene ie3 of mouse cytomegalovirus is essential for viral growth. J. Virol. 74: 11129-11136.
39. Parganas, E., D. Wang, D. Stravopodis, D. J. Topham, J. C. Marine, S. Teglund, E. F. Vanin, S. Bodner, O. R. Colamonici, J. M. van Deursen, et al. 1998. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93: 385-395.
40. Schaefer, L. K., S. Wang, and T. S. Schaefer. 1999. c-Src activates the DNA binding and transcriptional activity of Stat3 molecules: serine 727 is not required for transcriptional activation under certain circumstances. Biochem. Biophys. Res. Commun. 266: 481-487.
41. Coppo, P., I. Dusanter-Fourt, G. Millot, M. M. Nogueira, A. Dugray, M. L. Bonnet, M. T. Mitjavila-Garcia, D. Le Pesteur, F. Guilhot, W. Vainchenker, et al. 2003. Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene 22: 4102-4110.
42. Ilaria, R. L., Jr., and R. A. Van Etten. 1996. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271: 31704-31710.
43. Jostock, T., J. Müllberg, S. Ozbek, R. Atreya, G. Blinn, N. Voltz, M. Fischer, M. F. Neurath, and S. Rose-John. 2001. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268: 160-167.
44. Nadiminty, N., J. Y. Chun, Y. Hu, S. Dutt, X. Lin, and A. C. Gao. 2007. LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway. Biochem. Biophys. Res. Commun. 359: 379-384.
45. Deo, D. D., T. W. Axelrad, E. G. Robert, V. Marcheselli, N. G. Bazan, and J. D. Hunt. 2002. Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. J. Biol. Chem. 277: 21237-21245.
46. Zong, C. S., J. Chan, D. E. Levy, C. Horvath, H. B. Sadowski, and L. H. Wang. 2000. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J. Biol. Chem. 275: 15099-15105.
47. Akira, S., Y. Nishio, M. Inoue, X. J. Wang, S. Wei, T. Matsusaka, K. Yoshida, T. Sudo, M. Naruto, and T. Kishimoto. 1994. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77: 63-71.
48. Ichiba, M., K. Nakajima, Y. Yamanaka, N. Kiuchi, and T. Hirano. 1998. Autoregulation of the Stat3 gene through cooperation with a cAMP-responsive element-binding protein. J. Biol. Chem. 273: 6132-6138.
49. Nakajima, K., Y. Yamanaka, K. Nakae, H. Kojima, M. Ichiba, N. Kiuchi, T. Kitaoka, T. Fukada, M. Hibi, and T. Hirano. 1996. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 15: 3651-3658.
50. Wen, Z., Z. Zhong, and J. E. Darnell, Jr. 1995. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82: 241-250.
51. Knoblach, T., B. Grandel, J. Seiler, M. Nevels, and C. Paulus. 2011. Human cytomegalovirus IE1 protein elicits a type II interferon-like host cell response that depends on activated STAT1 but not interferon-g. PLoS Pathog. 7: e1002016.
52. Paulus, C., S. Krauss, and M. Nevels. 2006. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc. Natl. Acad. Sci. USA 103: 3840-3845.
53. Krauss, S., J. Kaps, N. Czech, C. Paulus, and M. Nevels. 2009. Physical requirements and functional consequences of complex formation between the cytomegalovirus IE1 protein and human STAT2. J. Virol. 83: 12854-12870.
54. Trilling, M., V. T. Le, and H. Hengel. 2012. Interplay between CMVs and interferon signaling: implications for pathogenesis and therapeutic intervention. Future Microbiol. 7: 1269-1282.
55. Fischer, P., U. Lehmann, R. M. Sobota, J. Schmitz, C. Niemand, S. Linnemann, S. Haan, I. Behrmann, A. Yoshimura, J. A. Johnston, et al. 2004. The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. Biochem. J. 378: 449-460.
56. Collison, L. W., G. M. Delgoffe, C. S. Guy, K. M. Vignali, V. Chaturvedi, D. Fairweather, A. R. Satoskar, K. C. Garcia, C. A. Hunter, C. G. Drake, et al. 2012. The composition and signaling of the IL-35 receptor are unconventional. Nat. Immunol. 13: 290-299.
57. Lau, J. F., I. Nusinzon, D. Burakov, L. P. Freedman, and C. M. Horvath. 2003. Role of metazoan mediator proteins in interferon-responsive transcription. Mol. Cell. Biol. 23: 620-628.
58. Sakamoto, S., R. Potla, and A. C. Larner. 2004. Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferonstimulated early response genes. J. Biol. Chem. 279: 40362-40367.
59. Karaghiosoff, M., H. Neubauer, C. Lassnig, P. Kovarik, H. Schindler, H. Pircher, B. McCoy, C. Bogdan, T. Decker, G. Brem, et al. 2000. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13: 549-560.
60. Matsumoto, M., N. Tanaka, H. Harada, T. Kimura, T. Yokochi, M. Kitagawa, C. Schindler, and T. Taniguchi. 1999. Activation of the transcription factor ISGF3 by interferon-gamma. Biol. Chem. 380: 699-703.
61. Müller, M., C. Laxton, J. Briscoe, C. Schindler, T. Improta, J. E. Darnell, Jr., G. R. Stark, and I. M. Kerr. 1993. Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-alpha and -gamma signal transduction pathways. EMBO J. 12: 4221-4228.
62. Zhu, M., S. John, M. Berg, and W. J. Leonard. 1999. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling. Cell 96: 121-130.
63. Gwack, Y., S. Hwang, C. Lim, Y. S. Won, C. H. Lee, and J. Choe. 2002. Kaposi's Sarcoma-associated herpesvirus open reading frame 50 stimulates the transcriptional activity of STAT3. J. Biol. Chem. 277: 6438-6442.
64. Lund, T. C., R. Garcia, M. M. Medveczky, R. Jove, and P. G. Medveczky. 1997. Activation of STAT transcription factors by herpesvirus Saimiri Tip-484 requires p56lck. J. Virol. 71: 6677-6682.
65. Smith, P. D., and M. R. Crompton. 1998. Expression of v-src in mammary epithelial cells induces transcription via STAT3. Biochem. J. 331: 381-385.
66. Yoshida, T., T. Hanada, T. Tokuhisa, K. Kosai, M. Sata, M. Kohara, and A. Yoshimura. 2002. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J. Exp. Med. 196: 641-653.
67. Zhang, L., K. Hong, J. Zhang, and J. S. Pagano. 2004. Multiple signal transducers and activators of transcription are induced by EBV LMP-1. Virology 323: 141-152.
68. Ulane, C. M., A. Kentsis, C. D. Cruz, J. P. Parisien, K. L. Schneider, and C. M. Horvath. 2005. Composition and assembly of STAT-targeting ubiquitin ligase complexes: paramyxovirus V protein carboxyl terminus is an oligomerization domain. J. Virol. 79: 10180-10189.
69. Hubackova, S., K. Krejcikova, J. Bartek, and Z. Hodny. 2012. Interleukin 6 signaling regulates promyelocytic leukemia protein gene expression in human normal and cancer cells. J. Biol. Chem. 287: 26702-26714.
70. Everett, R. D., and M. K. Chelbi-Alix. 2007. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89: 819-830.
71. Tavalai, N., P. Papior, S. Rechter, M. Leis, and T. Stamminger. 2006. Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J. Virol. 80: 8006-8018.
72. Ruzek, M. C., A. H. Miller, S. M. Opal, B. D. Pearce, and C. A. Biron. 1997. Characterization of early cytokine responses and an interleukin (IL)-6-dependent pathway of endogenous glucocorticoid induction during murine cytomegalovirus infection. J. Exp. Med. 185: 1185-1192.
73. Costa-Pereira, A. P., S. Tininini, B. Strobl, T. Alonzi, J. F. Schlaak, H. Is'harc, I. Gesualdo, S. J. Newman, I. M. Kerr, and V. Poli. 2002. Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc. Natl. Acad. Sci. USA 99: 8043-8047.
74. Netterwald, J., S. Yang, W. Wang, S. Ghanny, M. Cody, P. Soteropoulos, B. Tian, W. Dunn, F. Liu, and H. Zhu. 2005. Two gamma interferon-activated site-like elements in the human cytomegalovirus major immediate-early promoter/enhancer are important for viral replication. J. Virol. 79: 5035-5046.